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Abstract
Hematogenous dissemination of Mycobacterium tuberculosis (M. tb) occurs during both primary and reactivated tuberculosis
(TB). Although hematogenous dissemination occurs in non-HIV TB patients, in ,80% of these patients, TB manifests
exclusively as pulmonary disease. In contrast, extrapulmonary, disseminated, and/or miliary TB is seen in 60–70% of HIV-
infected TB patients, suggesting that hematogenous dissemination is likely more common in HIV+ patients. To understand
M. tb adaptation to the blood environment during bacteremia, we have studied the transcriptome of M. tb replicating in
human whole blood. To investigate if M. tb discriminates between the hematogenous environments of immunocompetent
and immunodeficient individuals, we compared the M. tb transcriptional profiles during replication in blood from HIV- and
HIV+ donors. Our results demonstrate that M. tb survives and replicates in blood from both HIV- and HIV+ donors and
enhances its virulence/pathogenic potential in the hematogenous environment. The M. tb blood-specific transcriptome
reflects suppression of dormancy, induction of cell-wall remodeling, alteration in mode of iron acquisition, potential evasion
of immune surveillance, and enhanced expression of important virulence factors that drive active M. tb infection and
dissemination. These changes are accentuated during bacterial replication in blood from HIV+ patients. Furthermore, the
expression of ESAT-6, which participates in dissemination of M. tb from the lungs, is upregulated in M. tb growing in blood,
especially during growth in blood from HIV+ patients. Preliminary experiments also demonstrate that ESAT-6 promotes HIV
replication in U1 cells. These studies provide evidence, for the first time, that during bacteremia, M. tb can adapt to the
blood environment by modifying its transcriptome in a manner indicative of an enhanced-virulence phenotype that favors
active infection. Additionally, transcriptional modifications in HIV+ blood may further accentuate M. tb virulence and drive
both M. tb and HIV infection.
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Introduction
Infection with M. tuberculosis (M. tb) is initiated by the few bacilli
in a droplet that are inhaled into the alveolus, which results either
in establishment of infection and progression to primary TB or, by
4–5 weeks post-infection, elicitation of immune responses that
control bacterial replication and result in latent TB. Studies in
animal models have demonstrated hematogenous dissemination of
M. tb from the lungs to various organs, including lymph nodes,
spleen, liver, pancreas, adrenal, and heart, as well as reseeding of
the lung, during primary infection [1,2,3]. Studies performed in
the pre-ATT (anti TB treatment) era demonstrated hematogenous
dissemination of M. tb in a majority of pediatric cases of primary
TB [4]. Viable M. tb have been demonstrated in lungs, liver,
spleen and kidneys of healthy individuals who died of causes
unrelated to TB, in a TB endemic setting [5]. This again provides
evidence of hematogenous dissemination of M. tb during primary
infection resulting in latent TB [5]. Bacteremia in TB patients with
pulmonary TB has been demonstrated for several decades [4,6,7].
Evidence for disseminated M. tb in patients who reactivated their
latent infection also exists [8]. Thus, bacteremia and hematoge-
nous dissemination of M. tb is an important component of the
natural course of establishment of infection and progression to
both primary and reactivated TB.
TB is one of the most common infections in HIV-infected
(HIV+) individuals in TB endemic countries, where 60–70% of the
HIV+ patients develop TB [9]. Co-infected individuals are at a
,20–40 fold higher risk for TB [10], and manifestation of TB is
independent of CD4+ T cell status and peripheral viral load
[11,12,13,14,15]. Extrapulmonary TB (EPTB), disseminated TB
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and miliary TB occurs in over 50% of the HIV+ TB patients
[16,17,18,19,20]. M. tb bacteremia is common in disseminated
TB, and has been increasingly reported in TB endemic regions
[21,22,23,24,25,26].
Despite the importance of hematogenous dissemination during
for establishment of latent TB, or progression to active disease,
how M. tb adapts to the blood environment to remains to be
investigated. Other pathogens such as Neisseria meningitidis, Listeria
monocytogenes, and Group A and Group B Streptococcus modulate
their transcriptional profiles during bacteremia [27,28,29,30].
Considering the exquisite sensitivity of M. tb to its environment
and its ability to adapt to different environments, it is likely that M.
tb also modulates its transcriptome during bacteremia. Transcrip-
tome changes have been described during adaptation of M. tb to
environments that may mimic in vivo conditions within the
granuloma or the phagosome [31,32,33,34,35,36]. M. tb also
modifies its transcriptional profile during adaptation to different
intracellular environments, [37,38]. Interestingly, differences in M.
tb transcriptomes during infection of immunocompetent (BALB/c)
and immunocompromised (SCID) mice has also been reported
[39]. Differential gene expression has been reported in bacteria
from different portions of the same granuloma, and in non-
granulomatous regions of the lung [40]. Thus, M. tb may also
discriminate between HIV- healthy and HIV+ immunodeficient
individuals during bacteremia.
We have investigated the transcriptome of M. tb replicating in
human whole blood to investigate the adaptation during
bacteremia. To determine how M. tb discriminates between the
blood environment of immunocompetent and immunodeficient
individuals, we have compared the transcriptional profile during
growth and replication in blood from HIV- and HIV+ donors.
Our results demonstrate that M. tb not only survives and replicates
in blood from both HIV- and HIV+ donors, it also enhances its
virulence/pathogenic potential in blood, more emphatically in
blood from HIV+ patients. The blood-specific transcriptome
reflects down-regulation of genes required for survival in
dormancy, induction of cell-wall remodeling, alteration in mode
of iron acquisition, potential evasion of immune surveillance, and
enhancement in the expression of important virulence factors that
drive active M. tb infection and dissemination. Importantly, these
changes are accentuated during replication in blood from HIV+
patients. Our results also demonstrate that esat6, the gene encoding
ESAT-6, which plays an important role in dissemination of M. tb
from the lungs, is upregulated in M. tb growing in blood [41,42],
especially in bacteria growing in HIV+ patient blood. Preliminary
experiments suggest that purified recombinant ESAT-6 promotes
HIV replication in U1 cells and could serve to directly accelerate
the progression of HIV-infection.
Results and Discussion
Transcriptome analysis of M. tb in whole blood from HIV-
and HIV+ humans
To investigate the transcriptome of M. tb in the hematogenous
environment, we first evaluated the ability of M. tb H37Rv to
survive and replicate in fresh whole blood from 10 HIV- and 15
HIV+ donors (Figure 1; TABLE S1). Significant bacterial growth
was observed within 96 hr post-inoculation in blood from both
HIV- and HIV+ donors (p values = 0.0020 and ,0.0001,
respectively). There was no difference in bacterial replication in
the two blood environments (p value = 0.2117) Fig 1A). At
96 hours post- inoculation, there was 3–46 fold (mean 21 fold)
increase in CFU in the blood from the 10 HIV- donors (Figure 1B).
The trend of M. tb replication was higher in blood from HIV+
donors (3–139 fold increase; mean = 39 fold) but the difference was
not statistically significant (Figure 1B). This is in contrast to earlier
studies where replication of BCG in whole blood from HIV- and
HIV+ children was studied, and the bacterial replication was
significantly higher in the latter environment. Whether the
difference in these results is due to use of BCG compared to
H37Rv, or differences in the pediatric and adult hematological
environment is not known [43]. While M. tb replication in 7H9
broth over 96 hr has been demonstrated in a number of previously
published studies, e.g., [44,45], the dilution of blood samples with
glutamine- and heparin- supplemented RPMI is unlikely to
promote M. tb replication since M. tb H37Rv failed to grow in
the medium alone (data not shown). Moreover, the same dilution
media was used in both HIV- and HIV+ blood cultures.
Following confirmation that human blood from both HIV- and
HIV+ donors supports bacterial survival and replication ex vivo
(Figure 1A), the transcriptional profile of M. tb replicating in blood
from 6 HIV- individuals and 6 HIV+ individuals was investigated
with bacteria grown in 7H9 bacterial media (Figure 2). (CD4+ T
cell numbers and viral load for the 6 HIV+ individuals is provided
in TABLE S1).
Analysis of the transcriptional profile of M. tb during replication
in blood from HIV- donors revealed that 91 genes were
upregulated and 60 were down-regulated (Figure 2). In contrast,
in bacteria replicating in blood from HIV+ patients, 157 genes
were upregulated and 136 down-regulated (Figure 2). Thus, a
more extensive transcriptional adaptation was observed in M. tb
replicating in the HIV+ blood environment. Of the differentially
expressed genes, 41 were upregulated and 17 down-regulated only
in blood from HIV- donors (Figures 2 and S1) and 107
upregulated and 93 down-regulated only in blood from HIV+
patients (Figures 2 and S2). Fifty upregulated and 43 down-
regulated genes overlapped in the two blood environments,
indicating a ‘‘blood-specific’’ transcriptional profile (Figures 2
and S3). Although the presence of heparin in the blood could
contribute to the differential expression of some M. tb genes, these
would be common for both the blood environments. Thus, M. tb
can adapt to the blood environment and can also distinguish the
blood environments of HIV- and HIV+ donors (see TABLE S2
and TABLE S3 for lists of all upregulated and down-regulated M.
tb genes in whole blood from HIV- and HIV+ donors,
respectively). Unsupervised hierarchical clustergrams for all
upregulated (Figure S4A) and down-regulated (Figure S4B) genes
produced 10 clusters for the former and 6 clusters for the latter
genes. As expected, M. tb genes differentially expressed only in
blood from HIV- donors or from HIV+ patients predominantly
clustered separately from each other, while genes differentially
expressed in both environments were spread across clusters.
For further verification of the differences in transcriptional
profiles during replication in blood from HIV+ versus HIV-
donors, the log2 ratio profiles obtained from the blood/7H9
microarray analyses were statistically evaluated (see Materials and
Methods) and M. tb genes exhibiting a $2 fold difference between
the two environments identified (Figure 3). Based on this analysis,
58 genes were upregulated and 28 down-regulated during growth
in HIV+ patient blood compared to HIV- donor blood (Figure 3).
The similarities between the transcriptional profiles in HIV- and
HIV+ blood, as well as the accentuated regulation in blood from
HIV+ donors is evident in Figure 3.
Functional distribution of M. tb genes differentially
expressed in blood from HIV- and HIV+ donors
The M. tb genes differentially expressed in the blood environ-
ment were categorized based on up- and down-regulation, in
Transcriptional Profiling of M. tb in Human Blood
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HIV- or HIV+ blood environments or both, and by functional
category (http://tuberculist.epfl.ch/index.html; TABLE 1,
Figure 4A,B). All functional categories exhibited some degree of
differential regulation during replication in the blood (TABLE 1);
however, Hypergeometric Distribution and Fisher’s Exact testing
did not reveal any particular functional category as being
significantly enriched in blood from either HIV- or HIV+ donors
(data not shown). Assessment of the proportion of differentially
expressed genes in any particular functional category showed that
genes annotated in the ‘‘insertional sequences and phages’’
(16.3%), ‘‘PE/PPE’’ (15.5%) and ‘‘conserved hypotheticals’’
(9.7%) were the top three functional classes affected; the roles of
these classes of genes in M. tb are largely unknown. The next most
regulated functional categories were ‘‘cell-wall and cell-wall
processes’’ (8.7%), and ‘‘virulence, detoxification, adaptation’’
(8.4%). Slightly less regulated were ‘‘intermediary metabolism and
respiration’’ (7.4%), ‘‘regulatory proteins’’ (7.1%), and ‘‘lipid
metabolism’’ (7.0%), and the least regulated was the ‘‘information
pathways’’ (4.5%) category. Based on the percentage of genes
affected within a functional category, the most upregulated
categories (Figure 4A), aside from ‘‘insertional sequences and
phages’’, were ‘‘PE/PPE’’, ‘‘lipid metabolism’’ and ‘‘cell-wall
processes’’. Similarly, the most down-regulated categories
(Figure 4B) include ‘‘insertional sequences and phages’’ and
‘‘PE/PPE’’, as well as ‘‘virulence, detoxification, adaptation’’ and
‘‘conserved hypotheticals’’. Interestingly, in nearly all functional
categories, the numbers of genes differentially expressed (both
upregulated and down-regulated) were higher in M. tb replicating
in blood from HIV+ donors (Figure 4) emphasizing the more
extensive transcriptional adaptation of M. tb to the HIV+ blood
environment.
M. tb dormancy-related transcriptome is suppressed
during replication in whole blood
M. tb dormancy is characterized by a viable, low metabolic,
anaerobic, non-replicating state associated with latent tuberculosis
infection [46]. The M. tb DevR (DosR) regulon consists of ,50
genes induced during adaptation to multiple stressful environ-
ments, including hypoxia encountered within granulomas [35,47]
and reactive nitrogen intermediates derived from activated
macrophages [48]. Such stresses can lead to inhibition of aerobic
respiration, suppression of bacterial replication, and M. tb
transition into a dormant state, contributing to latency [46]. The
DevR (DosR) response contributes to survival of M. tb under these
stresses and in the dormant state [49]. Compared to broth-grown
bacteria, several DevR (DosR) regulon genes were down-regulated
in M. tb replicating in whole blood (Figure 5A). Thus, Rv1812c,
Rv1813c, and Rv2031c (hspX), all predicted to be in the DevR
(DosR) regulon, were down-regulated in blood obtained from both
HIV- and HIV+ donors; an 18 DevR (DosR) regulon genes were
down-regulated in bacteria growing only in the blood from HIV+
patients. Fisher’s Exact testing revealed significant enrichment of
this regulon among down-regulated genes during replication in
blood from HIV+ patients but not in blood from HIV- donors
(Figure 5A), and 11 of the 28 genes down-regulated by M. tb in
blood from HIV+ patients versus HIV- donors (Figure 3) belong to
the DevR (DosR) regulon. Since the same logarithmically broth-
grown M. tb reference RNA was used across all microarray
experiments, the extensive down-regulation of this regulon in
HIV+ blood is not an artifact of the reference RNA. The vast
majority of the differentially expressed DevR (DosR) regulon genes
(19/21) group in hierarchical Cluster #6 (Figure S4B), and of the
61 genes in this cluster, 53 are down-regulated in blood from
HIV+ patients only (Figure S4B).
In addition to the DevR (DosR) regulatory system, the MprAB
(mycobacterial persistence regulator two-component system) also
participates in the establishment and maintenance of ‘‘persistence’’
during dormant M. tb infection [50]. The virulence-associated
operon encoding Rv1812c and Rv1813c, regulated by DevR
(DosR) and down-regulated in the blood environment, is also
regulated by the MprAB regulatory system [51]. Rv0982, the gene
encoding the sensor kinase of the system, MprB, is down-regulated
in M. tb replicating in blood from both HIV- and HIV+ donors; in
addition, Rv0981, encoding the response-regulator, MprA, is
down-regulated only in blood from HIV+ patients. Finally,
Rv1009, the gene encoding probable resuscitation-promoting
factor RpfB, believed to promote the resuscitation and growth of
dormant, non-growing bacteria [52], is upregulated during growth
in blood from HIV+ patients. Together these results suggest that
the blood environment does not produce stresses that lead to
inhibition of M. tb growth and transition to dormancy, implying
permissiveness for active bacterial replication. Moreover, in
addition to preventing entrance into dormancy, the HIV+ patient
blood environment may also promote exit from the dormant state.
Stress responses of M. tb in the blood environment
Transcripts for genes involved in global stress responses, e.g.
genes encoding RelA, universal stress proteins, sigma factors etc.,
Figure 1. M. tb replication in whole blood from HIV- and HIV+ subjects. (A) Total (intra- and extra-cellular) M. tb CFU counts after 2 and 96 hr
in blood from 10 HIV- donors or in blood from 15 HIV+ patients. (Wilcoxon Mann-Whitney two-tailed analysis; P values#0.05 statistically significant)
(B) M. tb CFU fold change between 2 hr and 96 hr in blood from HIV- donors and HIV+ patients (same as in panel A). (Mann-Whitney two-tailed
analysis; P value,0.05 statistically significant).
doi:10.1371/journal.pone.0094939.g001
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were either unaffected or down-regulated during replication in
whole blood. However, transcripts for Rv2429 (ahpD), involved in
the M. tb oxidative stress response, were upregulated in blood from
both HIV- and HIV+ donors; Rv2428 (ahpC) and Rv0462 (lpd)
were additionally upregulated in the latter environment. AhpD has
mild hydroperoxidase activity, and also functions, in conjunction
with Lpd and Rv2215 (DlaT) to reduce AhpC, an alkyl
hydroperoxidase which detoxifies organic peroxides [53], hydro-
gen peroxide (H2O2) [54], and peroxynitrate [55], indicating the
bacterial requirement for this antioxidative/antinitrosative system
during replication in blood. AhpC expression is repressed in M. tb
during in vitro broth culture, in macrophages and in mouse lungs
and spleen by an unknown regulator [56]. The derepression of the
AhpC system, and the upregulation of aphD, lpd, and aphC in the
HIV+ patient blood without any changes in expression of the katG
gene suggests that M. tb encounters source(s) of oxidative/
nitrosative stress that may not be neutralized by KatG.
Oxidative stress can be generated endogenously as free radical
byproducts of aerobic respiration accumulate [57], while exoge-
nous sources of oxidative stress can be experienced through
interactions with activated macrophages and neutrophils [57].
Thus, transcripts for Rv0249c, a succinic dehydrogenase involved
in the interconversion of fumarate and succinate, and Rv2200c
(ctaC), a probable transmembrane cytochrome C oxidase, both
involved in aerobic respiration were upregulated in blood from
both HIV- and HIV+ donors while genes involved in an
alternative respiratory pathway when aerobic respiration is
inhibited e.g. Rv0392c (ndhA), Rv1854c (ndh), Rv1162 (narH) and
Rv1164 (narI) were not affected. Another potential source of
oxidative stress for M. tb is an environment which is high in free
iron since iron drives the Fenton reaction which produces DNA
damaging active radicals [58]. As discussed below, based on the
transcriptional profile of M. tb in the blood environment, excess
free iron may be another plausible contributor to oxidative stress.
Another source of oxidative stress as well as nitrosative stress is
the intra-phagosomal environment of activated macrophages
where reactive species such as H2O2, superoxide (O
2-), and nitric
oxide (NO) are encountered [59]. Of these, NO represses M. tb
replication and the aerobic pathway [48,60], and low concentra-
tions of NO are known to initiate a transcriptional response in M.
tb characterized by the upregulation of the DevR (DosR) regulon
[48]. As discussed above, several of the DevR (DosR) regulon
genes were down-regulated during replication in blood (Fig 5A).
Also, the DevR (DosR)-regulated Rv1737c and Rv1736c (narK2X)
operon was down-regulated in the HIV+ patient blood environ-
ment. Rv1737c (NarK2) is involved in nitrate reduction when M.
tb is in a senescent stationary phase, as well as the transport of
nitrate in and nitrite out of the bacterium. Only low levels of narX
and narK2 transcripts are detectable in aerobic M. tb cultures [61].
Furthermore, nitrate reduction is associated with the respiratory
switch under hypoxic conditions [62] and has also been shown to
protect against acidic and nitrogen species stresses, conditions
associated with the intra-macrophage environment [63]. The
down-regulation of narX and narK2 in HIV+ patient blood is
consistent with the favoring of M. tb replication and aerobic
respiration in this environment. Stresses which lead to misfolding
of bacterial proteins activate a ‘‘heat shock response’’ in M. tb
[34,47,64]. M. tb encodes eight heat shock proteins (HSPs) which
function as molecular chaperones [65]. Transcripts encoding
HSPs Rv0384c (clpB), Rv0251c (hsp), Rv2031c (hspX), and Rv0440
(groEL2) were down-regulated in blood from both HIV- and HIV+
donors, and transcripts for HSPs, Rv3418c (groES) and Rv0350
(dnaK) were additionally down-regulated in HIV+ patient blood
(Figure 5B). Moreover, Rv0352 (dnaJ) and Rv0351 (grpE), both
Figure 2. Differentially expressed M. tb genes in whole blood
from HIV- and HIV+ donors. Heat map denoting upregulated genes
in red and down-regulated genes in green in M. tb grown in blood from
6 HIV- donors (1-6) and 6 HIV+ patients (7-12) with dye flip (12 samples
for each condition, HIV- and HIV+). Genes are listed as upregulated or
down-regulated in blood from both HIV- and HIV+ donors or in HIV-
donor blood only or HIV+ patient blood only. HIV+ blood sample codes
(H#) are listed at the bottom for comparison with CD4+ T cell counts
and viral loads in Table S1.
doi:10.1371/journal.pone.0094939.g002
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encoding proteins that are stimulators of DnaK activity, were also
down-regulated in HIV+ patient blood (Fig 5B). The down-
regulation of genes encoding heat shock proteins as a group is
statistically significant by Fisher’s Exact test in both blood
environments (Figure 5B), and suggests lack of stresses affecting
protein folding during growth in blood. HSPs are also highly
immunogenic [66] and proinflammatory [67], and overexpression
of M. tb HSPs reduces bacterial survival in mice lungs due to
enhanced immune recognition [68]. Consequently, HSPs are
considered potentially useful in the development of vaccines and
Figure 3. DifferentialM. tb gene expression in blood from HIV+ patients versus HIV- donors. (A) Heat map of M. tb genes upregulated$2
fold during replication in blood from HIV+ patients (7–12) versus HIV- donors (1-6). (B) Heat map of M. tb genes down-regulated $2 fold during
replication in blood from HIV+ patients (7-12) versus HIV- donors (1-6).
doi:10.1371/journal.pone.0094939.g003
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immunotherapy against TB [69,70]. The dampening of the ‘‘heat
shock response’’ could indicate evasion of M. tb from the host
immune surveillance.
M. tb cell-wall remodeling
The M. tb cell-wall is a complex structure serving as the
interface of the host and the pathogen, and is important for M. tb
survival and virulence [71]. The transcriptome of M. tb growing in
whole blood suggests that significant M. tb cell-wall remodeling
occurs in this environment. Specifically, the phthiocerol dimyco-
cerosate (PDIM) and phenol glycolipid (PGL) synthesis pathway
genes were particularly represented amongst the upregulated cell-
wall synthesis genes and statistically enriched in blood from HIV+
patients (Figure 5C). PDIM and PGL are closely related surface-
exposed cell-wall components present only in pathogenic myco-
bacteria and have been associated with virulence in animal models
[72]. Thus, transcripts for Rv2930 (fadD26), Rv2939 (papA5) and
Rv2953, all involved in PDIM biosynthesis, were upregulated in
blood from both HIV- and HIV+ donors. In addition, transcripts
for Rv2936 (drrA) and Rv2938 (drrC), both of which are involved in
the active transport of PDIM across the M. tb membrane were also
upregulated in the HIV+ patient blood, as was Rv2940c (mas)
which is involved in the elongation of mycocerosyl lipids,
components of both PDIM and PGL. Together these results
Table 1. Numbers of M. tb genes differentially expressed in blood from HIV- and/or HIV+ subjects arranged by functional category.
Functional Categorya Number of Genes Differentially Regulated in Blood
HIV- only HIV+ only Both HIV- and HIV+
Up Down Up Down Up Down Total
Conserved Hypotheticals (1042)b 17 9 18 31 13 13 101 (9.7%)c
Cell Wall and Cell Processes (772) 7 4 29 10 11 6 67 (8.7)
Intermediary Metabolism & Respiration (936) 10 3 20 20 7 9 69 (7.4%)
Virulence, Detoxification, Adaptation (239) 2 0 3 8 3 4 20 (8.4%)
Lipid Metabolism (272) 0 1 9 5 4 0 19 (7.0%)
PE/PPE (168) 1 0 9 5 6 5 26 (15.5%)
Regulatory Proteins (198) 1 0 4 6 1 2 14 (7.1%)
Information Pathways (242) 0 0 7 1 2 1 11 (4.5%)
Insertion Sequences and Phages (147) 3 0 8 7 3 3 24 (16.3%)
Total 41 17 107 93 50 43 351
aFunctional categories as designated in the Tuberculist website (http://tuberculist.epfl.ch/index.html).
bNumbers in parentheses indicate total number of genes in the category in the M. tb H37Rv genome.
cPercentages in parentheses next to ‘‘Total’’ numbers indicate the percentage of genes differentially expressed within the indicated category.
doi:10.1371/journal.pone.0094939.t001
Figure 4. Percentages of genes within functional categories differentially expressed in blood from HIV- and/or HIV+ donors. (A)
Upregulated genes arranged by functional category and corresponding blood environments. (B) Down-regulated genes arranged by functional
category and corresponding blood environments. (Functional categories as designated in the Tuberculist website http://tuberculist.epfl.ch/)
doi:10.1371/journal.pone.0094939.g004
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provide strong evidence that PDIM synthesis and transport by M.
tb is promoted in blood from HIV+ donors. This suggests that M.
tb can enhance its virulence during replication in blood from
HIV+ patients.
Transcripts for Rv2947c (pks15/1), Rv2948c (fadD22), and
Rv2950c (fadD29), all of which are involved specifically in the
synthesis of PGL, were upregulated in M. tb H37Rv exclusively in
HIV+ patient blood. PGL has been associated with ‘‘hyperleth-
ality’’ of M. tb HN878 [73] and correlates with increased bacterial
burden and dissemination in the rabbit CNS infection model [74].
While the M. tb H37Rv cell-wall lacks PGL due to a deletion
mutation in the pks15 gene which disrupts the PGL-specific
synthesis pathway [75], the potential upregulation of these PGL
synthesis genes in clinical M. tb strains which harbor a fully
functional Pks15/1 could result in a more aggressive phenotype.
Besides the genes involved in PDIM/PGL synthesis, 6 pe/ppe
genes were upregulated and 5 down-regulated in bacteria
replicating in blood from both HIV- and HIV+ donors; an
additional 9 pe/ppe genes were upregulated and 5 down-regulated
in HIV+ patient blood only (TABLE 1 and Figure 4). Only one pe/
ppe gene was exclusively upregulated in HIV- donor blood. PE/
PPE proteins are found only in mycobacteria, more commonly in
pathogenic species, and several are demonstrated to be cell-wall
proteins that contribute to virulence and pathogenesis [76,77,78].
The differential regulation of this class of proteins in the human
blood, and more extensively in HIV+ patient blood, is further
indication of cell-wall remodeling in this environment that may
alter the virulence of M. tb.
Upregulation of ESX-1 and ESX-5 type VII secretion
systems and genes encoding ESAT-6-like proteins
M. tb utilizes a variety of secretion systems to export proteins
across its cell-wall including the general (Sec) secretion system, the
twin-arginine translocation (Tat) system, and multiple type VII
secretion systems (T7SS) encoded within genomic loci termed
ESX-1 to ESX-5 [79]. Only the expression of T7SSs encoded by
ESX-1 and ESX-5 were extensively affected (Figure 6A,B). Genes
within the ESX-1 locus were statistically represented among
upregulated genes in both blood environments, while genes within
the ESX-5 locus were statistically represented among upegulated
M. tb genes in blood from HIV+ patients only (Figure 6A,B).
Rv3875 (esat-6), which encodes ESAT-6, an ESX-1 substrate,
was upregulated in bacteria replicating in blood from both HIV-
and HIV+ donors; in the latter environment, esat-6 was the most
highly upregulated gene (TABLE S3). Region of difference 1
(RD1), present in M. tb but absent from all BCG vaccine strains,
encompasses the ESX-1 locus, and M. tb Desat-6, M. tb DRD1 and
BCG are similarly attenuated for cell-cell spread of M. tb in vitro
and dissemination from the lungs to other organs in vivo [42,80,81].
ESAT-6 has been demonstrated to possess cytolytic activity for
macrophages, alveolar epithelial cells, and red blood cells (RBC)
and loss of ESX-1 or the ESAT-6 protein attenuates the cytolytic
capability of M. tb [41,42,82]. Dormant M. tb down-regulate esat-6
Figure 5. Specific categories of M. tb genes affected during
growth in the blood environment. (A) DosR regulon genes (B)
Genes encoding heat shock proteins (8) and stimulators of heat shock
proteins (2) (Total 10 genes assessed). (C) Genes involved in PDIM and
PGL synthesis and transport. Venn diagrams indicate numbers of genes
differentially expressed in blood from HIV- and/or HIV+ donors with
common affected genes in the overlap. (Green indicates down-
regulated. Red indicates upregulated.) Numbers in parentheses next
to headings indicate the total number of genes in the designated
category encoded in the M. tb genome. Tables below include the
Hypergeometric Probability P-values from Fisher’s Exact testing of
differentially expressed genes represented in each category and each
blood environment (HIV- or HIV+) (significant P-values in bold), as well
as the ranges of expression fold change.
doi:10.1371/journal.pone.0094939.g005
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[83], and the presence of antibodies to ESAT-6 in retrospective
sera obtained during the months prior to progression to clinical
TB from HIV+TB+ patients confirms the in vivo expression of
ESAT-6 during reactivation of latent TB [84]. In addition to esat-
6, transcripts for ESX-1 locus-specific genes, Rv3864 (espE) and
Rv3879c (espK), were upregulated in blood from both HIV- and
HIV+ donors, and Rv3878 (espJ) was additionally upregulated in
the HIV- donor blood. Rv3874 (cfp-10) which encodes the ESAT-
6 binding partner, CFP-10, and two PE/PPE encoding genes
within the ESX-1 locus, Rv3872 (pe35) and Rv3873 (ppe68) (known
to be ESX-1 substrates in M. marinum) [85,86], were upregulated
only in HIV+ patient blood. The upregulation of ESX-1 T7SS
and its substrate, ESAT-6; especially the expression of ESAT-6 in
HIV+ patient blood, implicate a major role for this system in M. tb
adaptation to the blood environment.
Several genes from the ESX-5 locus were also upregulated by
M. tb replicating in blood from HIV+ patients (Figure 6B). Thus
while Rv1787 (ppe25) was the only ESX-5 locus gene upregulated
in blood from both HIV- and HIV+ donors, Rv1792 (esxM),
Rv1798 (eccA5), Rv1790 (ppe27) and Rv1794 were upregulated in
HIV+ patient blood exclusively. In addition, genes encoding three
known substrates of the ESX-5 T7SS, located outside any ESX
loci, were also upregulated- Rv2430c (ppe41) and Rv0442c (ppe10)
in bacteria replicating in blood from both HIV- and HIV+ donors
and Rv2431c (pe25) in HIV+ patient blood alone. ESX-5 plays an
important role in the secretion of PE/PPE proteins [87,88], and
Figure 6. Upregulation of ESX loci and esat-6-like genes. (A) Genes upregulated within ESX-1 locus. (B) Genes upregulated within ESX-5 locus.
(C) Total genes encoding ESAT-6-like proteins upregulated in the M. tb genome. (D) Genes encoding ESAT-6-like proteins which are upregulated and
located outside of ESX loci. Venn diagrams indicate numbers of genes upregulated in blood from HIV- and/or HIV+ donors. Genes that are
upregulated in both environments are in the overlap. Numbers in parentheses next to headings indicate the total number of genes in the designated
category encoded in the M. tb genome. Tables below include the Hypergeometric Probability P-values from Fisher’s Exact testing of differentially
expressed genes represented in each category and each blood environment (HIV- or HIV+) (significant P-values in bold), as well as the ranges of
expression fold change. Note: Genes located within ESX-2, ESX-3, and ESX-4 loci were not differentially expressed in blood from either HIV- or HIV+
donors.
doi:10.1371/journal.pone.0094939.g006
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the upregulation of ESX-5 is consistent with the observation that
the family of PE/PPE genes is the second most upregulated
functional category in M. tb replicating in the blood (TABLE 1 and
Figure 4A). ESX-5 function has been linked to M. tb cell-wall
integrity and virulence [88]. Importantly, deletion of a region
encompassing five genes in the ESX-5 locus, Rv1787-Rv1791
(ppe25-pe19), attenuated M. tb growth in lungs and spleen of
intravenously infected SCID mice [88], suggesting a role for ESX-
5 in the hematogenous dissemination of M. tb. Coincidently, ppe25
and ppe27, located in the above described deleted region of ESX-5,
were upregulated in the HIV+ patient blood.
ESAT-6 belongs to a family of proteins called ‘‘ESAT-6-like’’
proteins, characterized by their small size (,100 amino acids),
helix-turn-helix structure, centrally located WXG motif, and
ability to be secreted despite the lack of a classical secretion signal
[89]. In total, M. tb encodes 22 ESAT-6-like proteins. Genes for 2/
22 ESAT-6-like proteins were upregulated during growth in blood
from HIV- donors; 8/22 were upregulated in HIV+ patient blood
making this group of genes significantly represented in the latter
Figure 7. qRT-PCR validation of microarray results. Log2 fold-changes in expression of seven selected genes in M. tb replicating in blood from
HIV- donors (black dots) or from HIV+ patients (open black circles) at 96 hr compared to M. tb logarithmically growing in 7H9 broth media. (A)
Microarray results from 6 biological replicates (6 different donors) per condition (blood from HIV- or HIV+ donors) with 2 technical replicates (Cy5/Cy3
dye swap) (total 12 values per condition are shown). (B) qRT-PCR results from M. tb replicating in blood from 6 different donors per condition (HIV- or
HIV+) (total 6 values per condition are shown). Y-axis values (Log2 fold change) of$1 indicate upregulation and values#-1 indicate down-regulation.
(For qRT-PCR, numbers of transcripts were normalized to copies of 16S rRNA.) P-values indicate the statistical difference between the average log2
fold-change of a gene in blood from HIV- subjects compared to HIV+ patient blood by Mann-Whitney two-tailed test.
doi:10.1371/journal.pone.0094939.g007
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environment (Figure 6C). Genes for ten of the 22 ‘‘ESAT-6-like’’
genes, including ESAT-6 and CFP-10 (also ESAT-6-like), are
located in tandem pairs within ESX loci, and the remainder are
located elsewhere in the genome (Figure 6D). Interestingly,
transcripts for 6 of the 12 ESAT-6-like proteins that are encoded
outside the ESX loci were upregulated in M. tb replicating in
blood; 1 in blood from HIV- donors and 5 in blood from HIV+
patients, giving statistical significance to the upregulation of this
group of genes in the HIV+ blood environment (Figure 6D). Thus,
while Rv3950c (esxF) is upregulated bacteria replicating in blood
from HIV- donors, Rv1038c (esxJ), Rv1197 (esxK), Rv1198 (esxL),
Rv2347c (esxP), and Rv3620c (esxW), were upregulated exclusively
during replication in the HIV+ patient blood. It is not known if the
secretion of these ESAT-6-like proteins occurs via the ESX-1 or
ESX-5 secretion systems. Also, while ESAT-6 and CFP-10 have
been studied extensively, the functions of the other ESAT-6-like
proteins remain to be investigated. (A categorized listing of all
upregulated ESX- and ESAT-6- related genes is provided in
TABLE S4.)
Iron acquisition by M. tb in whole blood
The mechanisms for acquiring iron during iron scarcity and
storing iron during excess are carefully orchestrated in M. tb in
response to the availability of iron [90]. No genes induced in low-
iron conditions were upregulated during growth in the blood
environment when compared to M. tb growing in Middlebrook
7H9 media which is high in free iron. In contrast, transcripts for
two iron-repressed genes, Rv1169c and Rv1463, were down-
regulated in blood from both HIV- and HIV+ donors. Rv2711,
the gene encoding IdeR, a transcriptional regulatory protein
which functions as an iron-binding repressor of siderophore
biosynthesis and iron uptake, was also upregulated in blood from
HIV- donors. Furthermore, the IdeR- and iron-induced gene
Rv3841, encoding the bacterioferritin BfrB, was upregulated by
M. tb in the HIV+ patient blood. The function of BfrB is to store
iron when it is in excess to avoid iron toxicity and to make it
available during times of iron scarcity [91]. Interestingly, BfrB
elicits antibody responses in both HIV- TB and HIV+ TB
patients, indicating that a high free iron environment is
experienced by M. tb during human infection [92,93]. Together
these transcriptional alterations indicate adequate supply of iron in
the M. tb- infected blood environment. These results were
unexpected since access to free iron in the host is typically limited
by high-affinity iron chelators such as transferrin in the blood and
ferritin within host cells [94], and M. tb siderophores are known to
acquire iron from transferrin [95], suggesting that alternative
mechanisms likely contribute to iron acquisition in the blood
environment.
Another mechanism by which iron can become available to
pathogens in the blood is through hemolysis [94]. Mechanisms for
iron acquisition from heme and heme-related molecules are
known in other bacteria [96,97], and M. tb has been shown to be
capable of acquiring iron from heme by a siderophore-indepen-
dent mechanism; however, genes responsible for M. tb import of
heme iron (Rv0202c-Rv0207c) and the gene encoding the secreted
heme-binding Rv0203 were also not affected in the blood
environment [98,99,100]. esat 6 is highly upregulated in the
HIV+ patient blood, and ESAT-6 has been demonstrated to lyse
Table 2. Comparison of M. tb genes differentially expressed in HIV- donor and/or HIV+ patient whole blood with corresponding M.
tb genes in the intra-macrophage environment from two published studies.
Gene(s) HIV- blooda HIV+ blooda THP-1b mBMM (activated)c
Rv3875 (esat-6) Up Up NDE Down
Rv3083 (mymA operon) Down Down Up NDE
Rv3084 (mymA operon) NDE NDE Up NDE
Rv3085 (mymA operon) NDE NDE Up NDE
Rv3086 (mymA operon) NDE NDE Up NDE
Rv3087 (mymA operon) NDE NDE Up NDE
Rv3088 (mymA operon) NDE Down Up NDE
Rv3089 (mymA operon) NDE Down Up NDE
Rv2029c (pfkB)* NDE Down Up Up
Rv2030c* NDE Down Up Up
Rv2031c (hspX)* Down Down Up Up
Rv3873 (ppe68) NDE Up Down Down
Rv3742c NDE Down Up NDE
Rv3841 (bfrB) NDE Up Down Down
Rv1169c (lipX, pe11) Down Down Up Up
Rv2930 (fadD26) Up Up Up Up
Rv2429 (ahpD) Up Up Up Up
Rv2430c Up Up Up Up
aThis study.
bhuman differentiated THP-1cell line (THP-1)- (Fontan P et al., 2008) (110).
cactivated murine bone marrow derived macrophages (mBMM)- (Schnappinger D et al., 2003) (37).
*Belongs to DevR (DosR) regulon.
‘‘Up’’ indicates upregulated, ‘‘Down’’ indicates down-regulated, ‘‘NDE’’ indicates ‘‘not differentially expressed’’. Note: The genes listed in this table are key to the studies
cited. This TABLE is a representative but not exhaustive list.
doi:10.1371/journal.pone.0094939.t002
Transcriptional Profiling of M. tb in Human Blood
PLOS ONE | www.plosone.org 10 April 2014 | Volume 9 | Issue 4 | e94939
RBCs [82]. It is tempting to speculate that the hemolytic activity of
ESAT-6 might contribute to providing a rich source of iron to M.
tb in the blood of HIV+ patients by releasing iron-bound
hemoglobin from RBCs.
Such hemolytic activity would lead to anemia, and in fact,
anemia is a common complication of TB [101]. While iron
deficiency, anemia of inflammation, and hemoptysis are all
contributors to TB-associated anemia [102], hemolysis due to
the activity of ESAT-6 (and possibly other ESAT-6-like proteins),
could potentially also contribute to driving anemia in HIV+ TB
patients with bacteremia. Interestingly, TB-associated hemolytic
anemia is resolved by successful treatment with ATT in the
absence of transfusions, corticosteroids, or iron supplementation
indicating that TB alone was the cause of anemia [103].
Furthermore, anemia and HIV seropositivity have been identified
as strong clinical indicators of mycobacteremia [104,105]. While
M. tb bacteremia can occur in both HIV- TB and HIV+ TB
patients [106,107], it is far more common in the latter cases
[24,108]. Host sequestration of iron in the blood is an important
mechanism against bacteremia; however, due to the release of
iron, persons with hemolytic disorders are more susceptible to
bacteremia with pathogens such as Salmonella and Pneumococcus,
[94,109]. The potential role of ESAT-6 in M. tb iron acquisition
during hematogenous dissemination and TB-associated anemia in
HIV+ patients remains to be investigated.
Quantitative real-time polymerase chain reaction (qRT-
PCR) validation of microarray results
Seven M. tb genes representing different functions and varying
levels of transcriptional regulation in blood from HIV- and HIV+
donors were selected for verification of the microarray results by
qRT-PCR (Figure 7). In contrast to the microarrays, the qRT-
PCR was performed on unamplified M. tb RNA. Genes chosen for
the qRT-PCR analysis included ESX-1 genes Rv3875 (esat-6),
Rv3874 (cfp-10), as well as DevR (DosR)-regulated genes Rv3134c,
encoding a universal stress protein, and Rv1735c, of unknown
function. Randomly selected genes included Rv0692, Rv1703c
and Rv2949c. In M. tb replicating in HIV+ patient blood, the four
genes that were upregulated in the microarrays (esat-6, cfp-10,
Rv1703c and Rv2949c) were also upregulated in the qRT-PCR
analysis, and the two selected genes down-regulated during growth
in HIV+ patient blood (Rv3134c and Rv1735c) were also down-
regulated in the qRT-PCR analysis. In comparison, all of the
selected genes, with the exception of esat-6, were not differentially
expressed in blood form HIV- donors in the microarray study. Of
these, four genes (cfp-10, Rv1703c, Rv2949c, and Rv1735c) were
also not differentially expressed by qRT-PCR analysis. In blood
from the HIV- donors, esat-6 was upregulated on the microarrays;
but was not statistically significantly differentially expressed by
qRT-PCR, although the results trended towards a positive fold
change. Similarly, while Rv0692 was down-regulated in blood
from HIV- donors by qRT-PCR, the differential expression on the
microarrays only trended towards a negative fold change. This
same gene was upregulated in blood from HIV+ patients by qRT-
PCR but only trended towards upregulation by microarray.
Rv3134c was down-regulated in HIV+ patient blood by both
assays and in blood from HIV- donors by qRT-PCR but was not
identified to be differentially expressed by microarray. Therefore,
Rv3134c (in blood from HIV- donors) was the only gene whose
expression did not mirror or trend similarly in both assays. For five
M. tb genes, the statistically significant difference between
expression in blood from HIV- donors versus HIV+ patients
coincided in both microarray and qRT-PCR analysis.
Comparison of M. tb transcriptional profile during
replication in blood and in macrophages
The transcriptional profile of M. tb in the intra-macrophage
environment has been investigated extensively [37,38,110]. A
Figure 8. Effect ofM. tb on HIV-1 p24 production by U1 cells. (A) Effect of gamma-irradiated, intact M. tb on p24 production by U1 cells over 5
days at increasing MOI (M. tb:cell). (B) Effect of M. tb subcellular fractions- cell wall, lysate, and culture filtrate proteins (CFP) at 20 ug/ml on U1 p24
production over 5 days. U1 culture medium alone represents the negative control in both assays. Shown are representatives of two or more
experiments.
doi:10.1371/journal.pone.0094939.g008
Table 3. Fold increase in U1 p24 production induced by M. tb
recombinant proteins.
Protein 0.5 ug/ml 1 ug/ml 2 ug/ml
ESAT-6 1.93+/20.69 20.3+/20.84 111.65+/235.7
CFP-10 0.69+/20.084 1.06+/20.61 0.44+/20.40
MS 1.41+/20.01 1.53+/20.007 1.92+/21.0
Numbers indicate the fold change in p24 levels in supernatants of protein-
treated cells at day 5 of incubation compared to p24 levels produced by U1
cells in wells with medium alone. Means and standard deviations from two
independent experiments are shown.
doi:10.1371/journal.pone.0094939.t003
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comparison of the key transcriptional adaptations of M. tb in the
macrophage (human differentiated monocytic cell-line THP-1
(THP-1) and activated murine bone marrow-derived macrophages
(mBMM) [37,110]), and in the blood reveals distinct responses to
the two environments (TABLE 2). While expression of some genes
differ in the two intra-macrophage environments, a number of M.
tb genes were upregulated in both THP-1 and mBMM; including
Rv0080, Rv0081, Rv1169c (pe11), Rv2028c, Rv2029c (pfkB),
Rv2030c, Rv2031c (hspX), Rv2032 (acg), Rv2429 (ahpD), Rv2430c
(ppe41), Rv2626c, Rv2930 (fadD26), Rv3133c, Rv3139 (fadE24),
and Rv3140 (fadE23) [37,110]. Of these, transcripts for Rv2930
(fadD26) and Rv2429 (ahpD) were also upregulated in blood from
both HIV- and HIV+ donors. Interestingly, Rv2430c (ppe41),
upregulated in both blood and intra-macrophage environments, is
an immunodominant B-cell inducer in patients with active TB,
primary and reactivated, as well as EPTB [111], and is a substrate
of the ESX-5 T7SS [88]. In contrast, Rv2031c (hspX) and
Rv1169c (pe11), were down-regulated in blood from both HIV-
and HIV+ donors, and Rv2029c (pfkB), and Rv2030c were
additionally down-regulated in HIV+ patient blood. The remain-
ing M. tb genes commonly upregulated in THP-1 and mBMM
were not differentially expressed by M. tb in the blood. Among M.
tb genes upregulated in the THP-1, but not affected in mBMM, is
the mymA operon (Rv3083-Rv3089). Rv3083 was down-regulated
in blood from both HIV- and HIV+ donors. Rv3088 and Rv3089
(fadD13) were additionally down-regulated in the HIV+ patient
blood. Rv3742c, a gene of unknown function, upregulated in
THP-1 but not affected in mBMM, was also down-regulated
exclusively in the HIV+ patient blood. Importantly, esat-6,
upregulated during replication in blood from both HIV- and
HIV+ donors, most strongly in the latter, was unaffected in THP-1
and down-regulated in mBMM.
The intra-macrophage is a low iron environment [60], thus
Rv3841 (bfrB), was down-regulated in both THP-1 and mBMM;
as mentioned above bfrB was upregulated in the HIV+ patient
blood. Also down-regulated in THP-1 and mBMM, Rv3873
(ppe68) of the ESX-1 locus is upregulated in the HIV+ patient
blood. DevR (DosR) regulon transcriptional responses in blood
and macrophages were conspicuously different; 3/48 and 21/48
genes were down-regulated during replication in blood from HIV-
and HIV+ donors, respectively (Figure 5A), while none were
down-regulated in THP-1 or mBMM, and in fact, 9 DevR (DosR)
regulon genes were upregulated in both THP-1 and mBMM and
an additional 32 were upregulated in the latter [37,110] (TABLE
S5 and Figure S5). The distinct transcriptional changes adopted by
M. tb replicating in the blood versus the macrophage indicates that
during hematogenous phase of infection, macrophages are not an
exclusive niche for M. tb.
ESAT-6 stimulates HIV replication in U1 cells
M. tb:HIV co-infection creates a synergistic environment which
drives and accelerates both infections [112,113]. HIV viral load
during the acute phase of TB is reported to increase 5–160 fold in
plasma [114], and viral burden in bronchoalveolar lavage fluid
(BAL) from TB-involved lung is higher than in BAL from
uninvolved lung of TB+ HIV+ patients or from TB- HIV+
patients indicating a local effect of M. tb on viral burden [115].
Additionally, blood monocytes from patients with active TB are
more susceptible to productive HIV-infection [116], and M. tb
PPD induces HIV replication in the U1 cell line, a model of HIV
latency containing HIV-1 proviruses [117]. Cell culture superna-
tants from U1 cells incubated with intact gamma-irradiated M. tb
H37Rv exhibited p24 production which increased in a M. tb dose-
dependent manner (Figure 8A). When U1 cells were stimulated
with subcellular fractions of M. tb, the cell-wall fraction dramat-
ically induced HIV replication while neither cell lysate nor culture
filtrate protein fractions induced appreciable p24 production
(Fig 8B). Purified recombinant ESAT-6 and two other cell-wall
proteins, CFP-10 and malate synthase (MS, Rv1837c), were tested
for their ability to stimulate HIV replication in U1 cells (TABLE 3);
only ESAT-6 induced HIV replication (.100 fold at 2 ug/ml; a
concentration not cytotoxic to U1 cells, data not shown). Neither
CFP10 nor MS induced significant HIV replication even at
concentrations as high as 10 ug/ml (data not shown). Preliminary
experiments with similar concentrations of the surface-exposed
and secreted antigens ERP, MPT51, and Ag85c (Rv3810,
Rv3803c, and Rv0129c, respectively) also failed to induce p24
production by U1 cells (data not shown). ESAT-6 is present in the
cell-wall, cell-membrane and the culture filtrates of M. tb
[118,119,120,121]. The inability of the culture filtrate fraction to
induce p24 production in our experiments (Figure 8B) is likely
because the CSU/BEI culture filtrate protein preparation method
excludes proteins ,10 kDa [122,123] and has little, if any ESAT-
6 (,6 kDa). These results specifically implicate ESAT-6 in the
synergistic interplay between M. tb and HIV during co-infection,
with an HIV+ environment stimulating the transcription of esat-6
and thus perhaps increasing M. tb virulence, and M. tb ESAT-6, in
turn, stimulating HIV replication in HIV-infected macrophages.
The mechanism(s) by which ESAT-6 drives HIV replication
merits further investigation.
Concluding Remarks
Hematogenous dissemination of M. tb occurs during the natural
course of establishment of latent infection leading to the systemic
seeding of the host organs [1,2,3,4,5,8]. Hematogenous presence
of M. tb is also frequently observed during both primary and
reactivation pulmonary and extrapulmonary TB, and in dissem-
inated and miliary TB. The ability of M. tb to adapt to the
physiological and immunological microenvironments it encounters
enables avoidance of the host anti-bacterial mechanisms and
transition between latent and active states. While the adaptation to
important environments such as the lungs, macrophages and the
granuloma have been investigated, scant information is available
regarding M. tb adaptation to the hematogenous environment.
HIV+ patients are at a significantly enhanced risk for active TB
infection and progression, for manifestation of extrapulmonary
and systemic forms of TB [10,16,17,18,19,20], and for M. tb
bacteremia [24,25,108,124]. The enhanced risk for TB arises
independently of CD4+ T cell numbers, viral load or antiretroviral
treatment, although the degree of risk correlates with immune
dysfunction [11,12,13,15,125,126]. Interestingly, studies with
HIV+ TB patients prior to and through the institution of Highly
Active Antiretroviral Therapy (HAART) showed that HAART
decreases the risk for pulmonary TB more than the risk for EPTB
[127], suggesting that treatment may have lower ability to
attenuate systemic dissemination. These cumulative observations
suggest that during residence in blood, M. tb itself alters its
phenotype to drive active TB, and more so in the blood from
HIV+ patients.
To our knowledge, this is the first investigation that specifically
delineates the ‘‘blood specific transcriptome’’ of M. tb and provides
insight into the bacterial mechanisms that likely drive active TB
and disseminated forms of TB. Thus, M. tb is capable of replicating
in and adapting to the blood of both HIV- healthy donors and
HIV+ patients (Figures 1 and 2). M. tb in the blood environment
undergoes a transcriptional adaptation indicative of a more
aggressive phenotype as demonstrated by the adaptation to an
active rather than dormant state, potential dampening of immune
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recognition by down-regulating the heat shock response, cell-wall
remodeling consistent with increased virulence, and upregulation
of ESX-1 and ESX-5 secretion systems and substrates associated
with virulence. Interestingly, the numbers of genes affected in each
of these categories were higher in M. tb replicating in blood from
HIV+ patients than in blood from the HIV- donors (Figures 5 and
6). We interpret this effect to be attributable to M. tb-adaptive
rather than HIV-driven mechanisms since the viral loads in nearly
all HIV+ blood patients were undetectable and the CD4+ T cell
counts in four of the six patients whose blood was used in the
microarray analysis were in the normal range (TABLE S1).
Importantly, the HIV+ patients included in this study were all
receiving HAART. It is likely that in blood from HIV+ HAART-
naı¨ve individuals the M. tb transcriptional adaptations might be
even more striking, and these studies are planned.
Another striking finding in this study was the dramatic
upregulation of the gene encoding the virulence factor, ESAT-6
during M. tb replication in both blood environments; esat6, was the
most upregulated of all genes in M. tb growing in blood from
HIV+ patients (Table S3). ESAT-6 is a cytolytic virulence factor
which participates in the bacterial crossing of the alveolar barrier
[41], and also has hemolytic activity that may facilitate M. tb access
to iron during the hematogenous phase of infection. Our
preliminary studies with recombinant purified ESAT-6 suggest
that it may also play a specific role in enhancing HIV replication
in the infected macrophages thus contributing to the accelerated
progression of HIV-infection to AIDS.
The whole blood model has been used to study the transcrip-
tional adaptation of other human bacterial pathogens during
bacteremia [27,28,29,30]. In contrast to studies with isolated cell-
types, the whole blood represents a complete environmental
context encountered in vivo during hematogenous phases of
infection. M. tb-infected neutrophils produce cytokines that can
activate macrophages, and dendritic cells, NK cells, and cd T cells
are involved in the innate immune responses to M. tb
[128,129,130,131,132]. Thus, the macrophage model may pro-
vide insufficient insight into the M. tb mechanisms that support
infection and disease progression. The whole blood model includes
all the cell types that participate in immune responses, including
macrophages, different T cell populations (CD4+, CD8+, TH17,
T regs), dendritic cells, monocytes, neutrophils (and other
granulocytes) etc as well as the resulting complex milieu of
cytokines and chemokines [133,134]. In fact, circulating cytokine
levels and other biomarkers have been shown to correlate with TB
disease and response to treatment [135,136], and the whole blood
model has been used to assay the ability of drugs to kill M. tb [137].
The comparison of the significant findings in this study with those
from published microarray studies of M. tb within macrophages
[37,110] highlights the differential responses of M. tb in the whole
blood environment and within isolated cells (Table 2).
The ability of M. tb to grow in whole blood ex vivo has been
suggested to correlate with virulence of the infecting M. tb strain
[138]. Our results suggest that M. tb alters its phenotype in the
hematogenous environment and adapts transcriptionally by
enhancing its virulence potential. Our studies also demonstrate
that M. tb can distinguish between the blood environments of
healthy, immunocompetent donors and of HIV+ patients. While
the current studies provide a snapshot of the transcriptional
adaptation in blood at a single time point in blood from HAART-
treated HIV+ patients, it is likely that M. tb adapts to the
continuously changing immunological environment in HIV+
patients to exploit the optimal opportunities for its growth, and
time spent in the hematogenous environment may also affect the
degree of adaptation. The results of this study will drive future
investigations aimed at understanding the pathogenesis of M. tb
and in the identification of diagnostic biomarkers and therapeutic
targets for active TB, M. tb bacteremia, and TB in HIV+
individuals.
Materials and Methods
Ethics Statement
Peripheral whole blood was collected from PPD-, healthy, HIV-
volunteers working at the Veterans Affairs Medical Center
(VAMC) with written informed consent signed by the participants
(NYU School of Medicine-IRB approved study #07-848; Board A
(IRB#1), FWA 00004952. Whole blood from de-identified HIV+
patients that otherwise would have been discarded after analysis
for CD4+ T cell counts and viral load assessment (NYUSoM, IRB
approved study #7279; Board B (IRB#2), FWA 00004952) was
also used in this study.
Human Subjects
Peripheral blood from 13 PPD-negative, HIV- healthy volun-
teers who had not received BCG vaccination and 17 HIV+
patients on HAART undergoing routine monitoring for viral loads
and CD4+T cells were obtained. The PPD status of the HIV+
donors was presumed to be PPD-negative since all were US born.
The details of CD4+ T cell count and viral load for each HIV+
patient included in these studies (CFU, Microarray, or qRT-PCR)
are listed in TABLE S1.
Whole blood M. tb culture
M. tb H37Rv was cultured in whole blood as described [139].
Briefly, whole blood was diluted 1:1 with RPMI-1640 supple-
mented with 1% L-glutamine and 20 IU/ml heparin (Sigma). Six
aliquots of diluted blood (0.9 ml) from each subject were
inoculated with 0.1 ml (106 CFU) of single cell suspensions of
log phase M. tb H37Rv grown in Middlebrook 7H9 media in 7 ml
endotoxin-free Sterilin non-pyrogenic tubes (Dynalab corporation)
and incubated at 37uC shaking at 20 rpm. For CFU determina-
tion, at 2 hr and 96 hr, three inoculated blood samples per subject
were treated with 0.1% triton X 100 (Sigma) in water containing
6M urea (Sigma) for 10 min at room temperature to lyse blood
cells. Lysed infected blood samples were centrifuged at 20006g for
15 min to collect the bacteria, and the pellets were washed once
with the same buffer and resuspended in MiddleBrook 7H9 media
with 0.05% Tween 80. For CFU determination, serial dilutions of
these suspensions were plated onto MiddleBrook 7H11 agar plates
and incubated at 37uC. After 14-21 days CFU were counted. CFU
counts from triplicate infections per time point were averaged.
Isolation of M. tb from blood cultures and extraction of
M. tb RNA
Ten-20 ml diluted whole blood was inoculated with M. tb
H37Rv (as described above) in 100 or 150 ml Sterilin endotoxin-
free containers (Dynalab corporation) and incubated at 37uC. At
96 hr post inoculation, blood cells were lysed, the bacteria pelleted
by centrifugation and the bacterial pellets were immediately
resuspended in GTC solution (4 M guanidium thiocynate, 0.5%
sodium N-lauryl sarcosine, 25 mM tri-sodium citrate pH 7.0,
0.1 M 2-mercaptoethanol and 0.5% tween 80) to lyse any
remaining eukaryotic cells. After washing once each with GTC
solution and 0.5% tween 80, the bacterial pellets were each
resuspended in 1 ml TRI reagent containing polyacrylamide
carrier (Molecular Research Center). For RNA isolation, the
bacilli were disrupted in a bead beater with autoclave-sterilized
0.1 mm zirconia beads (Biospec) and resulting lysates used to
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extract total RNA as described [140]. The RNA preparations were
cleaned by RNeasy columns (Qiagen) after treatment with Turbo
DNase (Ambion). RNA quality and quantity was determined using
an Agilent 2100 Bioanalyzer.
Log phase M. tb grown in 7H9 broth were treated similarly to
obtain reference RNA. Ten ml Middlebrook 7H9 media was
inoculated with a 0.5 ml frozen aliquot of bacteria (OD600 = 0.7
at time of storage) yielding a starting culture of OD600 ,0.035.
The culture was incubated at 37uC with shaking (110 rpm) for 7–9
days and harvested at an OD600 of 0.7–0.9 (mid to late log phase).
Bacteria similarly cultured enter stationary phase at OD600 ,1.4
to 1.7.
DNA Microarrays
RNA from M. tb cultured in blood from 6 PPD- HIV- healthy
donors and 6 HIV+ patients was used for the DNA microarray
studies with RNA from M. tb grown to log phase in Middlebrook
7H9 broth as the reference (see TABLE S1 for HIV+ donor
details). To ensure adequate amounts of RNA for the microarray
study, an RNA amplification strategy was used on similar amounts
of all M. tb RNA samples [141,142]. Briefly, each RNA sample
(100 ng) was amplified using MessageAmp II-Bacteria RNA
amplification kit (Ambion). Since this method produces aRNA in
antisense orientation, the synthesis of cDNA from aRNA and
fluorescent labeling of cDNA with Cy3 or Cy5 was accomplished
by first performing reverse transcriptase (RT) reaction with
Superscript II RT followed by labeling with Klenow fragment
using Bioprime Kit (Invitrogen) following a published method
[141]. This amplification method has been used to study
differential gene expression in several organisms [141], including
M. tb obtained from sputum samples of TB patients [142]. We first
confirmed that the expression profiles of amplified M. tb RNA
(aRNA) are similar to those of unamplified RNA, and the results
are consistent with earlier reported studies [143] (Figure S6). The
M. tb microarray chips containing 70-mer oligonucleotides
representing all open reading frames annotated in the M. tb
H37Rv genome sequence were obtained from the Center for
Applied Genomics (Public Health Research Institute; Newark, NJ).
Labeled cDNA from aRNA of log phase M. tb grown in 7H9 broth
was used as the reference control on each chip. For hybridization,
labeled cDNA probes generated from aRNA obtained from M. tb
grown in each blood sample was mixed with the labeled reference
cDNA probe prior to purification with Microcon YM10 filter
(Millipore). For each M. tb-infected blood sample, the M. tb arrays
were hybridized over night with the mixed labeled cDNA probes
in duplicate to include a Cy3/Cy5 dye swap [110]. The
microarrays were scanned and processed with an Axon 4000B
scanner and GenePix Pro 6.1 software, respectively. The chips
were normalized by the print-tip Lowess method, and the Cy5/
Cy3 intensity ratio was determined for each gene [144]. The
intensity ratio data obtained from M. tb grown in blood from all
subjects in the HIV- or HIV+ group was used to perform one class
Significance Analysis of Microarrays (SAM) with Multiarray
Viewer Software on the TMEV website for determination of
differentially expressed genes of M. tb grown in whole blood
compared to 7H9 broth grown M. tb [145]. Among genes
identified by SAM, only genes differentially expressed in the blood
environments compared to 7H9 broth that showed a $2 fold
change at a false discovery rate of ,2% were considered
significantly differentially expressed. Data were deposited in Gene
Expression Omnibus repository (Accession Number: GSE49760).
To contrast the M. tb differential gene expression in the two blood
groups (HIV+ vs HIV-) (Figure 3), HIV+/7H9 log ratios and
HIV-/7H9 log ratios (data obtained above) were directly
compared by two class unpaired SAM analysis, and a $2 fold
difference (HIV+ vs HIV-) at a false discovery rate of ,2% were
considered significantly differentially expressed.
Statistical Analysis
Hierarchical clustering of total upregulated and total down-
regulated genes was performed using TMEV MeV_4_9_0
software with the distance threshold set at 0.75. Fisher’s Exact
Test (Microsoft Fisher’s Exact Test Calculator) was applied to the
data to determine the hypergeometric probability of enrichment
amongst functional catergories of interest.
Quantitative RT-PCR
To validate the differential expression of M. tb genes identified
in the microarray, expression of seven selected genes was
determined in unamplified RNA from M. tb grown in blood from
6 HIV- and 6 HIV+ subjects (TABLE S1) by qRT-PCR [41]. M.
tb gene specific primers were designed using Primer3 software
(TABLE S6). Briefly, M. tb RNA was subjected to synthesis of first-
strand cDNA using Superscript II RNase H- reverse transcriptase
(RT). The real-time PCR was performed using iQ SYBR Green
supermix, primers, and cDNA in a MyiQ2 two color Real Time
PCR Detection System (Bio-Rad). For each RNA, a reaction
without RT was performed as a negative control. For quantitation,
a standard curve was generated for each gene using a serial
dilution of M. tb genomic DNA and respective primers. Copies of
16S rRNA was used to normalize the transcript levels of the
respective genes. The ratio of normalized copies of each selected
gene from M. tb grown in blood from HIV- or HIV+ subjects to
normalized copies in 7H9 broth-grown M. tb was calculated to
determine the fold change in expression of that gene in HIV- or
HIV+ blood compared to reference 7H9 broth. Prior to
quantitation, the specificities of PCR products were verified by
amplification of each gene target using respective primers with M.
tb H37Rv genomic DNA and cDNA obtained from M. tb RNA
isolated from infected blood as templates and sequencing of
amplified products. Mann-Whitney two-tailed test using Graph-
Pad prism software was used for statistical analysis, and P-
value,0.05 was considered statistically significant.
Culture of U1 cells
U1 cell line which is a chronically infected clone from the parent
promonocyte cell line, U937, and contains two HIV-1 pro-viruses
integrated into the genome, was obtained from the NIH AIDS
Research and Reference Reagent Program (Rockville, MD). The
U1 cells were grown in RPMI 1640 medium (Cambrex, MD)
supplemented with 10% of fetal calf serum, 2 mM L-glutamine
and 1% penicillin /streptomycin at 37uC in a 5% CO2 incubator.
Cells were diluted to 26105/ml and passaged every 5 days. Low
level of p24 (,100–400 pg/ml) was detected at day 5 from the
supernatant of untreated U1 cells. Cell viability was monitored by
trypan blue exclusion and more than 95% cells were viable on day
5.
Treatment of U1 cells with c-irradiated M. tb
U1 cells were washed twice with RPMI. One ml of U1 cell
suspension (26105 cells) was suspended in wells of a 24-well plate
and duplicate wells incubated with c-irradiated M. tb H37Rv at
multiplicities of infection (MOI) (bacteria:cell) ranging from 8:1 to
80:1. The plates were incubated at 37uC in a 5% CO2 incubator,
and 100 ul/well supernatant removed daily for 5 days and
replaced by 100 ul of fresh medium to maintain constant volume.
The collected viral supernatants were mixed with 100 ul of PBS
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with 0.05% Tween 20 (PBST) containing 2% Triton X 100 and
frozen until tested by p24 ELISA described below.
Treatment of U1 cells with M. tb subcellular fractions
Subcellular fractions of H37Rv (total cell lysate, cell-wall, and
culture filtrate proteins (CFP) were obtained from the NIH/
NIAID TB Research Materials and Vaccine Testing Contract,
Colorado State University (CSU), Fort Collins (currently provided
by (BEI Resources: www.beiresources.org) and were incubated in
duplicate with U1 cells (26105 cells in 1 ml) at final concentrations
of 4 ug/ml, 20 ug/ml, and 100 ug/ml in cell culture medium at
37uC in 5% CO2 for five days (representative data with cell
fraction concentrations of 20 ug/ml is shown). Incubation of cells
with cell culture medium alone was used as a negative control.
Cells were allowed to settle and 100 ul supernatants of treated and
untreated cells were collected daily for 5 days and subjected to p24
ELISA as described below.
Treatment of U1 cells with purified M. tb proteins
Purified M. tb proteins (ESAT-6, CFP-10, and malate synthase)
were also obtained from the above source at CSU. U1 cells were
incubated with increasing concentrations (0, 0.5, 1, and 2 mg/ml)
of the 3 purified proteins for 5 days at 37uC in 5% CO2. On day 5,
cells were allowed to settle and 100 ul supernatants of treated and
untreated cells were collected. P24 was measured by ELISA. Fold
increase in p24 production was determined by dividing the
amount of p24 detected in the supernatant of protein-treated cells
with the amount of p24 detected in the supernatant of untreated
cells on day 5 of incubation.
Measurement of p24 production by U1 cells
The concentration of p24 in the supernatants of U1 cell cultures
was measured by an in-house ELISA described previously [146].
Briefly, ELISA wells were coated with 100 ul of human MAb 91-5
(anti-HIV p24 antibody) [147] at 0.5 mg/ml at 4uC overnight.
The wells were washed 4 times with PBS- 0.05% Tween 20
(PBST) and blocked with 0.2 ml of 5% bovine serum albumin
(BSA) in PBST (BSA-PBST) for 6 h at 37uC. After washing the
wells again 4 times, 100 ul/well of each supernatant was added.
To generate a standard curve for quantitation of p24 in the test
samples, recombinant p24 from HIV-1SF2 expressed in yeast
(Chiron Corp., Emeryville, CA) was reconstituted to contain
250 pg/ml; 100 ul/well of serial two-fold dilutions (250 to
15.6 pg/ml) of each concentration of p24 was added in duplicate
wells in the ELISA plate. The plates were incubated at 4uC
overnight and then washed 4 times with PBST. One hundred ul of
biotinylated human anti-p24 MAb 241-D (which recognizes a
different p24 epitope from that recognized by MAb 91-5)
[147,148] diluted 1:10,000 in PBST-1%BSA was added to each
well and ELISA plate incubated at 37uC for 2.5 hr. After
subsequent washing, the wells were incubated with streptavidin
alkaline phosphatase 1:1000 (Invitrogen, Carlsbad, CA) for 1 hr at
37uC. Color was developed with an ELISA Amplification System
(Invitrogen), and plates were read at 490 nm. The amount of p24
was determined by extrapolating the optical density value of the
test sample supernatant on the curve plotted from the values
obtained with the recombinant p24. Every experiment was
repeated at least twice.
Supporting Information
Figure S1 M. tb genes differentially expressed in blood
from HIV- donors only. Heat maps of (A) upregulated M. tb
genes and (B) down-regulated M. tb genes. Results are shown from
M. tb grown in blood from 6 HIV- donors (1-6) and 6 HIV+
patients (7-12) with dye flip.
(TIF)
Figure S2 M. tb genes differentially expressed in blood
from HIV+ patients only. Heat maps of (A) upregulated M. tb
genes and (B) down-regulated M. tb genes. Results are shown from
M. tb grown in blood from 6 HIV- donors (1-6) and 6 HIV+
patients (7-12) with dye flip.
(TIF)
Figure S3 M. tb genes differentially expressed in blood
from both HIV- and HIV+ subjects. Heat maps of (A)
upregulated M. tb genes and (B) down-regulated M. tb genes.
Results are shown from M. tb grown in blood from 6 HIV- donors
(1-6) and 6 HIV+ patients (7-12) with dye flip.
(TIF)
Figure S4 Unsupervised Hierarchical Clustergrams of
M. tb genes differentially expressed in blood. Cluster-
grams of (A) upregulated M. tb genes and (B) down-regulated M. tb
genes from M. tb grown in blood from 6 HIV- donors (1-6) and 6
HIV+ patients (7-12) with dye flip. Distance threshold of
hierarchical tree was set to 0.75 producing 10 clusters among
upregulated genes and 6 clusters among down-regulated genes.
Key insert defines numbers in parenthesis (Black- total # genes in
cluster; Blue- # of cluster genes affected in HIV- donor blood
only, Pink- # of cluster genes affected in HIV+ patient blood only,
Orange- # of cluster genes affected in blood from both HIV- and
HIV+ donors.
(TIF)
Figure S5 Differential expression of DevR (DosR)
regulon genes in blood and macrophages. Venn diagrams
of numbers of DevR (DosR) regulon genes (A) down-regulated in
M. tb replicating in blood from HIV- and/or HIV+ subjects with
commonly down-regulated genes in the overlap (this study) and (B)
upregulated in M. tb isolated from THP-1 and/or activated
mBMM macrophages with commonly upregulated genes in the
overlap (Fontan P et al., 2008; Schnappinger D et al., 2003)
[110,37]. Note: No DevR (DosR) regulon genes were upregulated
in either blood environment nor were any down-regulated in
either macrophage environment.
(TIF)
Figure S6 Validation of RNA Amplification Method. (A)
Images of representative M. tb chips scanned after hybridization
with a mixture of Cy3 and Cy5 labeled cDNA probe derived from
unamplified and amplified RNA (aRNA) from M. tb grown in
HIV- blood and 7H9 broth (reference RNA). (B) Comparison of
differentially expressed ($2-fold) M. tb gene profiles in blood with
reference to 7H9 broth obtained with unamplified RNA and
aRNA; 257/617 (42%) genes identified to be differentially
expressed by unamplified RNA were also identified by aRNA.
(C) Heat map comparing highly differentially expressed ($4-fold)
M. tb gene profiles in blood with reference to 7H9 broth obtained
with unamplified and aRNA (three technical replicates including
one dye flip); 58/82 (71%) differentially expressed genes identified
by unamplified RNA were also identified by aRNA.
(TIF)
Table S1 Clinical details of HIV+ blood donors and
corresponding experiments.
(DOCX)
Table S2 M. tb genes differentially expressed in blood
from HIV- donors.
(PDF)
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Table S3 M. tb genes differentially expressed in blood
from HIV+ patients.
(PDF)
Table S4 M. tb ESX loci-related genes and genes
encoding ESAT-6-like proteins outside ESX loci upregu-
lated in blood from HIV- and/or HIV+ subjects.
(DOCX)
Table S5 Distribution of differentially expressed DevR
(DosR)-regulon genes in blood from HIV- and/or HIV+
subjects in this study and in two published intra-
macrophage microarray studies.
(DOCX)
Table S6 Primers used for qRT-PCR.
(DOCX)
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